Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Biomarin Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action

Biomarin Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action

If approved, Brineura will be the first and only treatment for CLN2 disease, a form of Batten disease.

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.

XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection

XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection

XBiotech's efforts to shade Xilonix's clinical failings amounted to little more than hand waving when it mattered most. European regulators at the oral explanation meeting on Thursday were not fooled.

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

Alpine Immune Sciences, a cancer immunotherapy company founded by former Dendreon CEO Mitch Gold, is listing publicly through a merger with Nivalis Therapeutics.